Haemonetics CORP 8-K filings

Haemonetics Corporation reported a robust first quarter for fiscal year 2027, exceeding expectations with a 5.6% revenue increase and raising its full-year guidance.

Haemonetics Corporation announced the election of Martin Madaus to its Board of Directors and shareholder approval of amendments to its Long-Term Incentive Compensation Plan and Employee Stock Purchase Plan.

Haemonetics Corporation is consolidating its reportable segments into Apheresis and MedSurg to better align with its internal management structure.

Haemonetics Corporation announced fourth quarter and fiscal year 2026 financial results, highlighting revenue growth and providing fiscal 2027 guidance.

Long-serving director Charles J. Dockendorff has announced he will not seek re-election at the upcoming 2026 Annual Meeting of Shareholders.

Haemonetics Corporation announced the full repayment of its $300 million 0.00% Convertible Senior Notes due 2026 using cash on hand and its revolving credit facility.

Haemonetics Corporation announced the publication of its 2024-2025 Corporate Responsibility Report, now available on its website.

Haemonetics Corporation reported strong third-quarter and year-to-date fiscal 2026 financial results, leading to an upward revision of its full-year guidance.

Haemonetics Corporation announced the acquisition of Vivasure Medical Limited for $100 million, expanding its presence in the percutaneous vessel closure market.

Haemonetics Corporation reported strong second-quarter fiscal 2026 results, raising its full-year guidance for revenue and adjusted earnings per diluted share, driven by profitable growth and disciplined execution.

Haemonetics Corporation reported a 4.4% decrease in Q1 FY26 revenue to $321.4 million, while reaffirming its full fiscal year 2026 guidance.

Haemonetics Corporation's 2025 Annual Meeting saw shareholders overwhelmingly approve all proposals, including the re-election of all nine directors, the advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor.

Haemonetics Corporation reports fourth quarter and fiscal year 2025 results, showing revenue growth and margin expansion, and provides fiscal 2026 guidance.

Haemonetics Corporation announced the appointment of Frank Chan as Executive Vice President, Chief Operating Officer, and the promotion of Roy Galvin to Executive Vice President, Chief Commercial Officer, effective March 3, 2025.

Haemonetics Corporation announced its third quarter and year-to-date fiscal 2025 results, along with updated fiscal 2025 guidance, showcasing revenue growth and margin expansion.

Haemonetics Corporation completes the sale of its whole blood assets to GVS, S.p.A. for a total consideration of up to $67.8 million.

Josep Llorens, Executive Vice President of Global Manufacturing and Supply Chain at Haemonetics, has announced his retirement effective July 11, 2025.

Haemonetics has agreed to sell its whole blood assets to GVS for $44.6 million in cash, with potential for an additional $22.5 million based on future performance.

Haemonetics Corporation announced positive second quarter fiscal 2025 results, with revenue growth and increased profitability, while also updating its full-year guidance.

Haemonetics Corporation reports that Executive Vice President and Chief Technology Officer, Anila Lingamneni, will depart from the company on November 1, 2024.

Haemonetics Corporation announced its first quarter fiscal 2025 results, showing revenue growth but a decrease in profitability, while reaffirming its full-year guidance.

Haemonetics Corporation amended its previous 8-K filing to correct a clerical error regarding the fiscal year in a proposal description from its 2024 Annual Meeting of Shareholders.

Haemonetics Corporation successfully held its 2024 Annual Meeting of Shareholders, electing all director nominees and ratifying the appointment of Ernst & Young LLP as its auditor.

Haemonetics Corporation successfully issued $700 million in convertible senior notes, using the proceeds to repurchase existing 2026 notes, pay down its revolving credit facility, and for general corporate purposes.

Haemonetics has priced a $600 million convertible senior notes offering and will repurchase $200 million of its 2026 notes.

Haemonetics Corporation plans to offer $525 million in convertible senior notes due 2029 through a private placement.

Haemonetics Corporation announced positive financial results for the fourth quarter and fiscal year 2024, alongside providing its fiscal year 2025 guidance.

Haemonetics Corporation has entered into a second amended and restated credit agreement, extending the maturity date of its credit facilities to April 2029 and increasing its revolving credit facility.

Haemonetics Corporation has finalized its acquisition of Attune Medical, a move that includes an upfront payment of $160 million and potential future payments based on sales growth and milestones.

Haemonetics Corporation has announced a definitive agreement to acquire Attune Medical for $160 million in cash upfront, plus contingent payments, to expand its presence in the electrophysiology market.